BioCentury
ARTICLE | Strategy

Legal cannons roll out in cyclosporine wars

February 16, 1999 8:00 AM UTC

In a long-expected move to protect its cyclosporine franchise, Novartis Pharmaceuticals Corp. sued SangStat Medical Corp. alleging that SANG's SangCya infringes Novartis' U.S. Patent No. 5,389,382 and seeking a permanent injunction to prevent marketing of SangCya.

Novartis also took aim at the FDA, simultaneously filing a suit alleging that the agency violated its own statutes in approving SangCya as a generic equivalent of Novartis's Neoral cyclosporine because SangCya is not identical to Neoral...